Xu Kexin, Shao Xuejie, Lu Ruilong, Liao Yixi, Zhao Yakun, Wang Bo, Qiu Zhiguang, Tian Yange
Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2025 Jul 4;20:2211-2226. doi: 10.2147/COPD.S513071. eCollection 2025.
Bufei Yishen formula (BYF) is an effective treatment strategy for chronic obstructive pulmonary disease (COPD). Effective-component compatibility of BYF III (ECC-BYF III), composed of 5 active ingredients (ginsenoside Rh1, paeonol, astragaloside, icariin and nobiletin) from BYF, has similar effects to BYF in intervening COPD. The abnormal structure and hypofunction of lung air-blood barrier induces inefficiency gas exchange and promotes development of COPD. However, the role of ECC-BYF III in the air-blood barrier remains unknown. This study dedicated to exploring the effect and mechanism of ECC-BYF III improve structure and function of lung air-blood barrier in COPD.
A COPD rat model was established to study the treatment of ECC-BYF III against COPD. The protective effect of ECC-BYF III on COPD was evaluated through pulmonary function and lung tissue pathology. The structure damage of the lung air-blood barrier was assessed using electron microscopy and immunofluorescence. Finally, we proved the regulating effect of ECC-BYF III in oxidative via the Nrf2 pathway.
The ECC-BYF III could significantly alleviate reduced pulmonary function, decrease damage of lung tissue and regulate oxidative stress in COPD rats. And ECC-BYF III reduced thickness of respiratory membrane, ameliorated damage of pulmonary capillary endothelial cells (PCECs) and alveolar epithelial cells (AECs) in COPD rats. Also, ECC-BYF III protected the function and normal cell morphology of type I alveolar epithelial cell (AT I) and type II alveolar epithelial cell (AT II) in COPD rats. Lastly, ECC-BYF III was indicated to adjust the Nrf2 pathway to improve oxidative stress and protect lung air-blood barrier in COPD rats.
ECC-BYF III protects lung air-blood barrier in COPD by regulating oxidative stress via Nrf2 pathway.
补肺益肾方（BYF）是治疗慢性阻塞性肺疾病（COPD）的有效策略。补肺益肾方Ⅲ号（ECC-BYFⅢ）由补肺益肾方中的5种活性成分（人参皂苷Rh1、丹皮酚、黄芪甲苷、淫羊藿苷和川陈皮素）组成，在干预COPD方面具有与补肺益肾方相似的作用。肺气血屏障结构异常和功能减退导致气体交换效率低下，促进COPD的发展。然而，ECC-BYFⅢ在气血屏障中的作用尚不清楚。本研究致力于探讨ECC-BYFⅢ改善COPD肺气血屏障结构和功能的作用及机制。
建立COPD大鼠模型以研究ECC-BYFⅢ对COPD的治疗作用。通过肺功能和肺组织病理学评估ECC-BYFⅢ对COPD的保护作用。使用电子显微镜和免疫荧光评估肺气血屏障的结构损伤。最后，我们通过Nrf2途径证明了ECC-BYFⅢ在氧化应激中的调节作用。
ECC-BYFⅢ可显著缓解COPD大鼠肺功能下降，减轻肺组织损伤并调节氧化应激。ECC-BYFⅢ还可降低COPD大鼠呼吸膜厚度，改善肺毛细血管内皮细胞（PCECs）和肺泡上皮细胞（AECs）的损伤。此外，ECC-BYFⅢ保护了COPD大鼠Ⅰ型肺泡上皮细胞（AT I）和Ⅱ型肺泡上皮细胞（AT II）的功能及正常细胞形态。最后，ECC-BYFⅢ被证明可调节Nrf2途径以改善氧化应激并保护COPD大鼠的肺气血屏障。
ECC-BYFⅢ通过Nrf2途径调节氧化应激来保护COPD大鼠的肺气血屏障。
